10-K/A: Enhabit Files Amendment to 10-K to Include Omitted Part III Information

Enhabit, Inc. files an amendment to its annual report on Form 10-K to include information previously omitted from Part III regarding directors, executive officers, and corporate governance.

Summary

• Enhabit, Inc. is filing Amendment No. 1 on Form 10-K/A to its Annual Report on Form 10-K, originally filed on March 6, 2025, to provide the information required in Part III of Form 10-K.
• The information was previously omitted from the Initial Filing in reliance on General Instruction G(3) of Form 10-K because the company intended to incorporate the required disclosures from its proxy statement relating to its 2025 Annual Meeting of Stockholders.
• The 2025 proxy statement, however, will not be filed within the requisite time period to allow incorporation by reference.
• This Amendment changes the Initial Filing by including the information required by Part III of Form 10-K (Items 10, 11, 12, 13 and 14).
• The amendment also includes currently dated certifications pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 from the principal executive officer and principal financial officer.
• The aggregate market value of the voting stock held by non-affiliates of the registrant as of the last business day of the registrant's most recently completed second fiscal quarter was $440.4 million.
• As of April 22, 2025, the registrant had outstanding 50,637,417 shares of common stock.
• The company's consolidated net revenue for 2024 was $1,034.8 million.
• The Adjusted EBITDA for 2024 was $100.1 million, a 2.6% year-over-year improvement.
• The company reduced its debt by $40.0 million, including $20.0 million in voluntary debt payments.

Sentiment

Score: 5

Explanation: The document is largely factual and descriptive, with some positive elements (e.g., debt reduction, quality of care metrics) balanced by negative elements (e.g., net loss, below-target EBITDA). The sentiment is neutral overall.

Positives

• Adjusted EBITDA improved 2.6% year over year, reaching $100.1 million in 2024.
• The company reduced debt by $40.0 million, including $20.0 million in voluntary payments.
• The company's 30-day hospital readmission rate was 20.0% better than the national average, and hospice visits in the last days of life were 41.6% better than the national average.
• Grew hospice census steadily throughout 2024 with the use of the case management model; average daily census increased sequentially every month in 2024 (beginning January with 3,433 and ending December with 3,729).

Negatives

• The Senior Management Bonus Plan (SMBP) paid out at only 25% of target due to not achieving target Adjusted EBITDA.
• Net loss was $(154.0) million.

Risks

• The document mentions shareholder activism and a strategic review process, indicating potential internal pressures or strategic uncertainties.
• The company is involved in litigation related to breach of fiduciary duty, which could result in financial and reputational risks.
• The company's compensation recoupment policy could lead to clawbacks of executive compensation in certain circumstances.

Future Outlook

The document does not contain specific forward-looking statements beyond the general strategic goals outlined in the executive compensation discussion.

Management Comments

• Barbara A. Jacobsmeyer, as our President and Chief Executive Officer, directs the strategic, financial, and operational management of the Company and, in this capacity, provides unique insights into its detailed operations.
• The Compensation Committee has focused on performance goals and metrics in the senior management bonus plan and the long-term equity incentive plan and peer alignment in the overall compensation program.

Industry Context

The document provides limited direct industry context, but the focus on home health and hospice services, payer innovation contracts, and quality of care metrics aligns with broader trends in the healthcare services industry.

Comparison to Industry Standards

• The document mentions comparing the company's compensation practices to a peer group including companies like Addus HomeCare Corporation, Amedisys, Inc., and National HealthCare Corporation.
• The company's 30-day hospital readmission rate was 20.0% better than the national average, and hospice visits in the last days of life were 41.6% better than the national average, indicating strong performance relative to national benchmarks.

Management Changes

Corporate Governance

Legal Proceedings

• The company is involved in a lawsuit, Enhabit, Inc. et al v. Nautic Partners IX, L.P. et al., pending in the Chancery Court of Delaware, asserting claims for breach of fiduciary duty, aiding and abetting, and usurpation of corporate opportunity arising from actions involving its former officers.

Stakeholder Impact

• Executive compensation decisions are designed to align management's interests with those of long-term stockholders.
• The company's performance and governance practices impact employees, customers, and other stakeholders.

Next Steps

• The company will continue to monitor and manage its executive compensation program to align with performance and shareholder interests.
• The Compensation Committee will set the FCFPS goal for each year of the performance period at the start of such year.
• The company expects that each non-employee member of the Board will receive a similar annual grant of RSUs valued at $150,000 in 2025.

Key Dates

Keywords

executive compensation, corporate governance, directors, EBITDA, financial performance, Enhabit, Form 10-K/A, amendment